While semaglutide only targets and binds to GLP-1 receptors, tirzepatide is a dual agonist that acts on both GLP-1 and GIP receptors
When fatigue occurs in patients taking GLP-1 receptor agonists, it may be directly related to the medication, secondary to the physiological changes these drugs induce (such as reduced caloric intake or altered glucose metabolism), or entirely unrelated to the treatment
Patients receive counseling on hydration, electrolytes, and protein intake, which are critical to maintaining muscle while taking appetite-suppressing medication
Increasing heart rate
The analysis did not account for the effect of potential confounding factors such as drug interactions, previous health conditions, and use of multiple medications
Baseline (before starting GLP-1 or supplements): 25-hydroxyvitamin D (target: 30-50 ng/mL) Vitamin B12 (target: above 400 pg/mL) Serum iron, ferritin, and TIBC Serum magnesium Serum zinc Complete metabolic panel CBC (to check for anemia) Follow-up testing at 3 and 6 months: Repeat all baseline labs Add: body composition measurement (DEXA scan is gold standard) to track lean mass vs fat mass changes Assess supplement adherence and adjust doses based on results The cost of basic nutritional bloodwork is minimal compared to the cost of undiagnosed deficiencies